rFVIII‐Fc in severe haemophilia A: The incentive switch in case of high risk of joint bleedings
- 27 June 2022
- journal article
- research article
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 52 (10), e13824
- https://doi.org/10.1111/eci.13824
Abstract
Background Efmoroctocog alfa, the first recombinant factor VIII fusion protein with extended half-life (rFVIII-Fc), has been hypothesized to lower FVIII consumption in patients with severe Haemophilia A (pwSHA), without reducing clinical efficacy. What about real life? Method MOTHIF-II was a noninterventional, multicentre, before/after study, via the collection of retrospective data from July 2015 to June 2016 (called T1), and from July 2017 to June 2018 (called T2), in 7 French haemophilia treatment centres. We examined the prescriptions and dispensations of factor VIII and the Annual Bleeding Rate (ABR), in pwSHA without current inhibitors on prophylaxis, before and after the introduction of rFVIII-Fc. The data gathered from the BERHLINGO research database and from the French Healthcare claims database with a determinist pairing process based on the national unique identification number. Results A total of 156 pwSHA were included in the prescription cohort and 83 in the ABR cohort. For switched patients, the mean amounts of prescribed FVIII were significantly higher during T1 compared to T2 (4333 (2052) vs. 3921 (2029) IU/kg/year/patient, p: 0.028); a significant decrease in their ABR was also observed between T1 and T2 (6.3 (6.0) vs. 4.4 (5.4), p: 0.047). These patients had a more severe bleeding profile centred on haemarthrosis. Conclusion The results are related to those of the pivotal clinical trials for the reduction in FVIII consumption following the switch to rFVIII-Fc, with a significant improvement in the haemorrhagic phenotype for pwSHA.Keywords
Funding Information
- Swedish Orphan Biovitrum (Investigator Sponsored Study Sobi‐HAEM89‐001)
This publication has 28 references indexed in Scilit:
- Value of a national administrative database to guide public decisions: From the système national d’information interrégimes de l’Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in FranceRevue D'epidemiologie Et de Sante Publique, 2017
- Switching to extended half‐life products in Canada – preliminary dataHaemophilia, 2017
- Future of haemophilia outcome assessment: registries are key to optimized treatmentJournal of Internal Medicine, 2016
- The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) StatementPLoS Medicine, 2015
- Recombinant factor VIII Fc fusion protein: extended‐interval dosing maintains low bleeding rates and correlates with von Willebrand factor levelsJournal of Thrombosis and Haemostasis, 2014
- Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia ABlood, 2014
- Treatment of haemophilia: building on strength in the third millenniumHaemophilia, 2011
- A catalogue of reporting guidelines for health researchEuropean Journal of Clinical Investigation, 2009
- Back to the future: a recent history of haemophilia treatmentHaemophilia, 2008
- Haemophilias A and BThe Lancet, 2003